To ensure the robustness of our approach, we validated the method with established positive control outcomes where IL6 signaling inhibition has proven efficacious, including for rheumatoid arthritis, polymyalgia rheumatica, and COVID-19. This evidence concerns the gene IL6 and polymyalgia rheumatica.